These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29878859)

  • 61. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.
    Bass K; Longest W
    AAPS PharmSciTech; 2020 May; 21(5):157. PubMed ID: 32451773
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler.
    Dolovich MB; Kuttler A; Dimke TJ; Usmani OS
    Int J Pharm X; 2019 Dec; 1():100018. PubMed ID: 31517283
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.
    Hindle M; Longest PW
    Pharm Res; 2010 Sep; 27(9):1800-11. PubMed ID: 20454837
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.
    Longest PW; Tian G; Khajeh-Hosseini-Dalasm N; Hindle M
    J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):461-481. PubMed ID: 27082824
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
    Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
    Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aerosol Delivery Devices for Obstructive Lung Diseases.
    Pleasants RA; Hess DR
    Respir Care; 2018 Jun; 63(6):708-733. PubMed ID: 29794206
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Flow Structure and Particle Deposition Analyses for Optimization of a Pressurized Metered Dose Inhaler (pMDI) in a Model of Tracheobronchial Airway.
    Ahookhosh K; Saidi M; Mohammadpourfard M; Aminfar H; Hamishehkar H; Farnoud A; Schmid O
    Eur J Pharm Sci; 2021 Sep; 164():105911. PubMed ID: 34129919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.
    Geller DE
    Respir Care; 2005 Oct; 50(10):1313-21; discussion 1321-2. PubMed ID: 16185367
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dry powder inhaler aerosol deposition in a model of tracheobronchial airways: Validating CFD predictions with in vitro data.
    Ahookhosh K; Saidi M; Aminfar H; Mohammadpourfard M; Hamishehkar H; Yaqoubi S
    Int J Pharm; 2020 Sep; 587():119599. PubMed ID: 32663586
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Davis MD; Saunders JL; Ringer C; Engberg R; Zhao Y; DiBlasi RM; Rubin BK
    J Breath Res; 2023 Apr; 17(3):. PubMed ID: 36996807
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler.
    Farr SJ; Rowe AM; Rubsamen R; Taylor G
    Thorax; 1995 Jun; 50(6):639-44. PubMed ID: 7638806
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.
    Newman SP; Brown J; Steed KP; Reader SJ; Kladders H
    Chest; 1998 Apr; 113(4):957-63. PubMed ID: 9554631
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
    Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
    Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The importance of selecting the right type of inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD)].
    Larsson K; Bjermer L; Svartengren M
    Lakartidningen; 2019 Feb; 116():. PubMed ID: 30720857
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
    Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
    AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition.
    Ammari WG; Khalil Mohammad M; Tayyem RF
    Pulm Pharmacol Ther; 2019 Oct; 58():101829. PubMed ID: 31352077
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Genuair® inhaler: a novel, multidose dry powder inhaler.
    Chrystyn H; Niederlaender C
    Int J Clin Pract; 2012 Mar; 66(3):309-17. PubMed ID: 22340451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.